Olympus America

Press Center

Olympus Plasma Hysteroscopic Resection and Vaporization Unveiled at the 2017 American Congress of Obstetricians and Gynecologists Annual Meeting

Bipolar resection has FDA 510(k) clearance in gynecology, having shown lower risks of electrolyte imbalance, compared to monopolar resection

Olympus has received FDA 510(k) clearance of claims that the bipolar electrosurgery featured with its plasma hysteroscopic resection and vaporization system has lower risks of electrolyte imbalance (hyponatremia) compared to monopolar electrosurgery. This advantage can lead to improved patient outcomes. During the gynecological procedure, plasma is created by the combination of radio frequency, energy and saline. Due to its conductivity, the plasma allows the energy to cross into the targeted tissue at lower energy levels than with more traditional approaches. This effect leads to lower operating temperatures and therefore less thermal spread.

CENTER VALLEY, Pa., (May 4, 2017) - Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today that it has released the new plasma hysteroscopic resection and vaporization full portfolio of products. These products have received FDA 510(k) clearance of claims that the bipolar electrosurgery featured with its plasma hysteroscopic resection and vaporization system has lower risks of electrolyte imbalance (hyponatremia) compared to monopolar electrosurgery. In addition to improved patient outcomes, the system benefits include precision in cutting, better visibility, and cost-savings potential through the portfolio of plasma-enabled electrodes for a wide range of hysteroscopic procedures.

Plasma resection and vaporization, used in other medical specialties, creates an electrically conductive gas cloud of vapor and charged particles. During gynecologic procedures, plasma is created by the combination of radio frequency, energy and saline. Due to its conductivity, the plasma allows the energy to cross into the targeted tissue at lower energy levels than with more traditional approaches. This effect leads to lower operating temperatures and therefore less thermal spread.

The Olympus 8.5 mm hystero-resectoscope, for use with the world's first 4 MM high definition telescope, is designed with extra-low dispersion glass and offers several dedicated plasma electrodes, offering a variety of treatment options in gynecology:

  • Vaporization electrodes, which eliminate the need for chip removal (removing the need for multiple resectoscope reinsertions and designed for procedural efficiency).
  • Variety of loop sizes for resection and coagulation of polyps, myomas and the endometrium, which allows for fewer cuts, thereby enabling quicker resection and operating time.
  • Needle electrode for septum removal.

"The Olympus plasma hysteroscopic resection and vaporization system advances operative hysteroscopy to a new level of capability," said Dr. Benjamin Gocial at Main Line Fertility.

"Olympus builds upon its excellent track record with plasma resection and vaporization through this 510(k) clearance, and we expect enthusiastic adoption of the technology in gynecology," said Randy Clark, Group Vice President of the Surgical Division at Olympus America Inc. "We have aimed not only to bring improved patient outcomes to our customers, but to provide an advanced gynecology portfolio that is cost effective for Hospitals and Ambulatory Surgery Centers."

The plasma hysteroscopic system will be showcased at the American Congress of Obstetricians and Gynecological Annual Meeting (ACOG) May 6-9 in San Diego, CA at booth #948. To learn more about the plasma hysteroscopic resection and vaporization system from Olympus, please call 1-800-848-9024 or visit us at http://medical.olympusamerica.com/procedure/hysteroscopy

# # #

About Olympus Medical Systems Group
Olympus Medical Systems Group, a division of global technology leader Olympus, develops solutions for healthcare professionals that help improve clinical outcomes, reduce overall costs and enhance quality of life for their patients. By enabling less invasive procedures, innovative diagnostic and therapeutic endoscopy, and early stage lung cancer evaluation and treatments, Olympus is transforming the future of healthcare. For more information visit Olympus at www.medical.olympusamerica.com.